BSE filing, NSE: NATCOPHARM. Summary written from the filing by ALFA Finder's alert engine.
Natco Pharma Ltd: key numbers
- Share price
- ₹793.00
- Market cap
- ₹15,556 Cr
- Revenue (annual)
- ₹4,078 Cr
- Net profit (annual)
- ₹1,418 Cr
- P/E (TTM)
- 13.6×Sector 46.1×
- Promoter holding
- 49.39%-0.03% QoQ
- FII holding
- 15.99%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Natco Pharma Ltd
All →Natco Pharma Capital Structure Change
Natco Pharma's ₹1,279.4 Crore rights issue closed on October 22, 2026. Shares were priced at ₹750 each on a ₹2 face value.
- Value
- ₹1,279 Cr
Natco Pharma Product Launch
Natco Pharma launches Carboplatin Injection, a Paraplatin® generic, in the U.S. market via its subsidiary. The oncology product addresses a critical U.S. supply shortage.
Natco Pharma Share Pledge
Promoter V.C. Nannapaneni pledged 850,000 shares of Natco Pharma, valued at ₹67.10 Crore. This pledge creation increases encumbrance on promoter shareholding.
- Value
- ₹67.10 Cr
Natco Pharma Fund Raise of ₹2,000 Cr
Natco Pharma shareholders approved fund raising of up to Rs. 2,000 Crore through various instruments, along with other routine AGM resolutions.
- Value
- ₹2,000 Cr
Natco Pharma Annual General Meeting
Natco Pharma held its 43rd Annual General Meeting on September 30, 2026. Shareholders approved all agenda items, including a fund-raising authorisation limit of Rs. 2,000 Crore.
Natco Pharma Annual General Meeting
Natco Pharma Limited conducted its 43rd Annual General Meeting on September 30, 2026. Shareholders considered a proposal to raise up to ₹2,000 Crore through various equity instruments.
- Value
- ₹2,000 Cr
Other other announcement announcements
All →Mahindra & Mahindra Financial Services Other Announcement
Mahindra & Mahindra Financial filed its ALM statement as of September 30, 2026, submitted to RBI. It is a periodic regulatory return with no new transaction.
ACME Solar Holdings Other Announcement
ACME Solar filed the CARE Ratings monitoring agency report on its Rs.2,800 crore QIP for the quarter ended 30 September 2026. The report shows no deviation from the offer objects.
eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.